New radioactive nanoparticle targets tough tumors in early trial

NCT ID NCT06184035

Recruiting now Disease control Sponsor: Spago Nanomedical AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target tumors using tiny particles. The main goals are to check safety, find the right dose, and see if it can shrink tumors. About 90 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED SOLID TUMOR METASTATIC CANCER RECURRENT SOLID TUMOR REFRACTORY CANCER SOLID TUMOR UNRESECTABLE SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cancer Research South Adelaide
RECRUITING

Adelaide, South Australia, 5000, Australia
St Vincent Hospital Melbourne
RECRUITING

Melbourne, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.